Soluble CD137 as a dynamic biomarker to monitor agonist CD137 immunotherapies
Glez-Vaz J, Azpilikueta A, Olivera I, Cirella A, Teijeira A, Ochoa MC, Alvarez M, Eguren-Santamaria I, Luri-Rey C, Rodriguez-Ruiz ME, Nie X, Chen L, Guedan S, Sanmamed M, Gracia J, Melero I. Soluble CD137 as a dynamic biomarker to monitor agonist CD137 immunotherapies. Journal For ImmunoTherapy Of Cancer 2022, 10: e003532. PMID: 35236742, PMCID: PMC8896037, DOI: 10.1136/jitc-2021-003532.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsBiomarkersCD8-Positive T-LymphocytesHumansImmunotherapyMiceNeoplasmsReceptors, Tumor Necrosis FactorConceptsMouse CD8 T cellsCD8 T cellsChimeric antigen receptorT cellsCD137 costimulationHuman CD137Surface expressionAnti-CD137 monoclonal antibodiesCAR-transduced T cellsCostimulatory molecule CD137Sequential plasma samplesCAR T cellsBasis of efficacyMouse tumor modelsProtein expression levelsCD137 agonistsSoluble CD137First patientSyngeneic tumorsAgonist agentsPharmacodynamic biomarkersClinical trialsPlasma concentrationsDynamic biomarkersSCD137